Stem Cell Therapy: Current Challenges and Translational Opportunities

Abstract

Stem cell therapy has emerged as a cornerstone of regenerative medicine, promising to repair, replace or rejuvenate damaged tissues and organs through the unique capabilities of stem cells to self-renew and differentiate. The translational pathway from bench to bedside, however, is fraught with biological, manufacturing, regulatory and ethical obstacles. Key challenges include heterogeneity of cell populations, limited engraftment and survival, immune rejection, tumorigenicity risk, scale-up of manufacturing and quality control, as well as high cost and regulatory complexity. Concurrently, numerous translational opportunities are being realized: advances in cell engineering, gene editing, biomaterial scaffolds, three-dimensional culture, improved delivery routes, and application of induced
pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs) in diverse clinical settings. This review synthesises current knowledge of stem cell types, their therapeutic applications, emerging trends, and compares approaches, with particular attention to translational bottlenecks and facilitators. It highlights that successful translation will depend not only on biological advances but also on robust manufacturing pipelines, standardised protocols, long-term safety monitoring, and regulatory harmonisation. The review concludes by proposing future directions for research, including personalised cell therapies, integration of organoid-based approaches, better patient stratification, and economic models to support sustainable deployment. Ultimately, achieving the promise of stem cell therapies requires concerted efforts across multidisciplinary domains to surmount the translational gap and deliver safe, effective treatments to patients.